ScreenerHero

KZIA Kazia Therapeutics Limited

NAS · US · Healthcare · Biotechnology · kaziatherapeutics.com
9.290USD+0.32%Mkt Cap: 144.45M $P/E: —

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap144.45M USD
Enterprise Value35.61M USD
Revenue (TTM)1.90M USD
Gross Profit1.90M USD
Net Income (TTM)-20.70M USD
Revenue/Share0.85 USD
Last Price9.290 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-779.03
PEG1.01
EV/EBITDA-2.00
EV/Revenue18.76
P/S75.83
P/B3.26
EPS (TTM)-6.85
EPS (Forward)-0.01
52W Range
4.86035% of range17.40
52W High17.40 USD
52W Low4.860 USD
Profitability
Gross Margin100.00%
Oper. Margin-14641.04%
EBITDA Margin0.00%
Profit Margin-49290.48%
ROE249.39%
ROA-341.56%
Growth
Revenue Growth312.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.28M USD
CapEx (TTM)—
FCF Margin57.93%
FCF Yield0.76%
Net Debt-69.36M USD
Net Debt/EBITDA3.89
Balance Sheet
Debt/Equity-0.05
Current Ratio2.87
Quick Ratio2.86
Book Value/Sh2.84 USD
Cash/Share6.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 14, 2017
Splits
Last Split1:5
Split DateApr 17, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.36 USD
Upside (mean)+205.3%
Target Range17.50 USD – 39.23 USD
17.50+205.3% to mean39.23
# Analysts6
Ownership
Shares Out.15.55M
Float9.39M
Insiders15.42%
Institutions31.70%
Short Interest
Short Ratio2.3d
Short % Float4.95%
Short % Out.4.95%
Shares Short769.53K
Short (prev mo.)559.16K
Technical
SMA 5012.08 (-23.1%)
SMA 20010.47 (-11.3%)
Beta2.27
S&P 52W Chg15.78%
Avg Vol (30d)285.64K
Avg Vol (10d)280.44K
Technical Indicators
RSI (14)32.4
MACD-0.8455
MACD Signal-0.8406
MACD Hist.-0.0049
BB Upper11.98 USD
BB Middle10.20 USD
BB Lower8.414 USD
BB Width34.98%
ATR (14)0.7438 USD
Vol Ratio (20d)0.50x